OncRef

Clinical Trial: NCT04684147

Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia

Status:

RECRUITING

Phase:

Phase 2

Lead Sponsor:Juventas Cell Therapy Ltd.
Information Provided By:Juventas Cell Therapy Ltd.
Last Update Posted:2025-08-08

Study Overview

Brief Summary

The study is a Phase II, single-arm, open-label, single-dose clinical trial, and its primary objective is to evaluate the efficacy and safety of CNCT19 Cell Injection in the treatment of CD19 positive Relapsed or Refractory acute lymphoblastic leukemia.

Official Title

Phase Ⅱ Clinical Trial of CNCT19 Cell Injection in the Treatment of CD19 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia

Conditions

Relapsed or Refractory Acute Lymphoblastic Leukemia

Intervention / Treatment

  • Biological: single dose of CNCT19

Other Study ID Numbers

  • HY001201

Start Date (Actual)

2020-12-24

Primary Completion Date (Actual)

2022-09-22

Study Completion Date (Estimated)

2026-12-31

Enrollment (Estimated)

100

Study Type

Interventional

Phase

Phase 2